UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2025
Commission File Number: 001-38283
InflaRx N.V.
(Translation of registrant’s name into English)
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
|
Form 20-F ☒
|
Form 40-F ☐
|
EXPLANATORY NOTE
As previously announced, on March 20, 2025, InflaRx N.V. (the “Company”) issued a press release titled, “InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones.”
A copy of the press release is attached as Exhibit 99.1 to this report on Form 6-K. Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
2
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
Press Release, dated March 20, 2025
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
INFLARX N.V.
|
||
|
Date: March 20, 2025
|
By:
|
/s/ Niels Riedemann
|
|
Name:
|
Niels Riedemann
|
|
|
Title:
|
Chief Executive Officer
|
|
4